Trial Parameters
Condition Lymphoma
Sponsor IRCCS Azienda Ospedaliero-Universitaria di Bologna
Study Type OBSERVATIONAL
Phase N/A
Enrollment 1,500
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2021-12-07
Completion 2026-08
Brief Summary
It is an observational, non-interventional, prospective, monocentric study, whose objective is to enroll 1500 patients with lymphoma in 5 years within the Institute of Hematology "Seragnoli".
Eligibility Criteria
Inclusion Criteria: * Age greater than or equal to 18 years at enrollment * Diagnosis of lymphoma within 3 months of enrollment * Patients may have been treated, as long as the initial diagnosis of lymphoma is within 3 months of enrollment * Signing of the informed consent form Exclusion Criteria: * none
Related Trials
NCT06137144
AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refra
View Trial →
NCT04739813
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR
View Trial →
NCT07305337
Randomised Controlled Trial of Artificial Intelligence-assisted Health Education
View Trial →